MedPath

Effects of Deep Brain Stimulation in Parkinson's Disease

Not Applicable
Conditions
Parkinson's Disease
Interventions
Procedure: Deep brain stimulation of the subthalamic nucleus
Registration Number
NCT00855621
Lead Sponsor
Oslo University Hospital
Brief Summary

The purpose of this study is to identify factors predicting good results in patients treated with deep brain stimulation for Parkinson's disease. The study includes a comparison of two surgical methods used to provide this therapy.

Detailed Description

The study will prospectively examine the effects of deep brain stimulation of the subthalamic nucleus (STN-DBS) on motor function, quality of life and cognitive function in Parkinson's disease (PD) patients treated at Rikshospitalet University Hospital. The aim is to identify which factors that predict good treatment outcome, in order to improve patient selection of this generally highly effective, but specialized and expensive treatment.

The study has several aims:

1. Randomized double-blind evaluation of the impact of using single vs. multiple electrode-recordings to guide electrode placement.

2. To identify factors predicting good effect on motor function and improvements of quality of life after deep brain stimulation of the subthalamic nucleus.

3. To identify cognitive and psychiatric changes related to deep brain stimulation of the subthalamic nucleus

4. To study social functioning of patients after STN-DBS and quality of life of patient caregivers

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Diagnosis of Parkinson's disease
  • Symptoms ≥ 5 years
  • Severity of Parkinson's disease ≥ 20 points in UPDRS motor scale (scale 0-108) in OFF medication state
  • Marked fluctuations of motor symptoms AND/OR troublesome dyskinesias AND/OR severe tremor AND/OR intolerable side-effects of dopaminergic drugs
  • Failure of medical treatment to sufficiently control symptoms
  • L-dopa responsive symptoms with ≥30% reduction in UPDRS motor score in drug ON state compared to OFF state OR severe l-dopa unresponsive tremor
Exclusion Criteria
  • Previous surgery for Parkinson's disease
  • Marked axial motor symptoms unresponsive to treatment with l-dopa
  • Dementia (Mattis dementia rating scale < 130).
  • Patient suffering from untreated moderate or major depression or anxiety disorder
  • Presence of other psychiatric disorder preventing necessary co-operation
  • Brain MRI showing marked atrophy or white matter changes
  • Increased risk of bleeding
  • Presence of medical illness with short life expectancy
  • Other surgical contra-indications

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Single microelectrodeDeep brain stimulation of the subthalamic nucleusSurgical procedure performed using single microelectrode recording guidance intraoperatively
Multiple microelectrodeDeep brain stimulation of the subthalamic nucleusSurgical procedure performed using multiple microelectrode recording guidance intraoperatively
Primary Outcome Measures
NameTimeMethod
Change from baseline of the motor score of the New-UPDRS (part III) OFF medication12 months
Secondary Outcome Measures
NameTimeMethod
Change in social functioning (Social adjustment scale-SR)12 months
Change from baseline in caregivers quality of life (Scale of Caregivers Quality of Life)12 months
Change from baseline in Mattis Dementia Rating Scale score12 months
Change from baseline of self-reported health-related quality of life (PDQ-39 Summary Index)12 months
Change from baseline of Clinical Dyskinesia Rating Scale score12 months
Change from baseline in ADL function (UPDRS part II)12 months
Frequency of new or worsened psychiatric symptoms12 months

Trial Locations

Locations (1)

Oslo University Hospital

🇳🇴

Oslo, Norway

© Copyright 2025. All Rights Reserved by MedPath